DiaMedica Therapeutics Inc. (NASDAQ:DMAC) is reporting second quarter financial results on Tuesday 11th August 2020, after market close.
Previous Quarter Performance
DiaMedica Therapeutics Inc. unveiled loss for the first quarter of $ 0.19 per share, from the revenue of . The quarterly earnings surged 38.46 percent while revenues compared with the same quarter last year.
The consensus estimates are in revenue The bottom line results street analysts by $ 0.06 or , at the same time, top line results analysts by $ 25.42 million or .
Stock Performance
According to the previous trading day, closing price of DMAC was $ 5.72, representing a 236.47 % increase from the 52 week low of $ 1.70 and a 35 % decrease over the 52 week high of $ 8.80.
The company has a market capital of $ 80.88 million and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 8th July 2020, initiated by Maxim Group at Buy rating, with $ 14.00 target price.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of recombinant proteins for the treatment of kidney and neurological diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company is also developing DM199 for the treatment vascular dementia; and DMDx, a diagnostic tool to measure human tissue kallikrein-1 levels.
